OBJECTIVE: To determine the prevalence and incidence rates of work disability in rheumatoid arthritis (RA), and to determine the effect of anti-tumor necrosis factor (TNF) therapy on work disability. METHODS: Participants with RA who were employed when RA was diagnosed (N = 8082) were evaluated for up to 5.5 years. Work disability incidence rates were determined in a subset (N = 4155) of those who stated they were currently employed, and the effect of anti-TNF therapy was determined by conditional logistic regression, after adjustment for covariates. RESULTS: At a median of 12.8 years after RA onset, 56.2% were still employed and 43.8% were not working. Of those not working, 22.7% considered themselves disabled. In addition, 30.5% had stopped work over their lifetimes for health reasons and 20.6% were currently receiving Social Security disability benefits. The annualized incidence rate for self-reported disability was 2.5% and for Social Security disability 1.9%. The incidence rate for persons who stopped working and did not resume employment was 4.0%. Anti-TNF therapy was not associated with Social Security disability, but was associated with an increased risk of self-reported disability (odds ratio 1.6) after adjustment for covariates. CONCLUSION: Rates of self-reported disability were lower than noted in previous studies, perhaps reflecting overall improvement in RA therapy. We could not discern a positive effect of anti-TNF therapy on the risk of work disability.
OBJECTIVE: To determine the prevalence and incidence rates of work disability in rheumatoid arthritis (RA), and to determine the effect of anti-tumor necrosis factor (TNF) therapy on work disability. METHODS:Participants with RA who were employed when RA was diagnosed (N = 8082) were evaluated for up to 5.5 years. Work disability incidence rates were determined in a subset (N = 4155) of those who stated they were currently employed, and the effect of anti-TNF therapy was determined by conditional logistic regression, after adjustment for covariates. RESULTS: At a median of 12.8 years after RA onset, 56.2% were still employed and 43.8% were not working. Of those not working, 22.7% considered themselves disabled. In addition, 30.5% had stopped work over their lifetimes for health reasons and 20.6% were currently receiving Social Security disability benefits. The annualized incidence rate for self-reported disability was 2.5% and for Social Security disability 1.9%. The incidence rate for persons who stopped working and did not resume employment was 4.0%. Anti-TNF therapy was not associated with Social Security disability, but was associated with an increased risk of self-reported disability (odds ratio 1.6) after adjustment for covariates. CONCLUSION: Rates of self-reported disability were lower than noted in previous studies, perhaps reflecting overall improvement in RA therapy. We could not discern a positive effect of anti-TNF therapy on the risk of work disability.
Authors: Maria N Tamborenea; Cecilia Pisoni; Sergio Toloza; Eduardo Mysler; Guillermo Tate; Dora Pereira; M García Carrasco; J Quintero; A Cappuccio; A Granel; M Lazaro; Pablo Arturi; Gustavo Citera; J Velazco Zamora; Veronica Saurit; A Alvarellos; S B Pons Estel; C Danielsen; C Graf; Sergio Paira; F Ceccatto; Javier Cavallasca; E Civit; J Moreno; A Estevez; M Diaz; Marcela Verando; Antonio Catalan Pellet; G Gomez; Pablo Maid; Ana Beron; Gabriela Salvatierra; Marcos Mendez; A Cusa; Oscar Rillo; M Paez; M Larraude; D Sohn; M Gallo; A Conforti; Veronica Malah; Patricio Tate; A Baños Journal: Rheumatol Int Date: 2014-06-20 Impact factor: 2.631
Authors: Mark A Lumley; Francis J Keefe; Angelia Mosley-Williams; John R Rice; Daphne McKee; Sandra J Waters; R Ty Partridge; Jennifer N Carty; Ainoa M Coltri; Anita Kalaj; Jay L Cohen; Lynn C Neely; Jennifer K Pahssen; Mark A Connelly; Yelena B Bouaziz; Paul A Riordan Journal: J Consult Clin Psychol Date: 2014-05-26
Authors: Leslie R Harrold; Becky A Briesacher; Dan Peterson; Ashley Beard; Jeanne Madden; Fang Zhang; Jerry H Gurwitz; Stephen B Soumerai Journal: J Rheumatol Date: 2013-01-15 Impact factor: 4.666
Authors: Tuulikki Sokka; Hannu Kautiainen; Theodore Pincus; Suzanne M M Verstappen; Amita Aggarwal; Rieke Alten; Daina Andersone; Humeira Badsha; Eva Baecklund; Miguel Belmonte; Jürgen Craig-Müller; Licia Maria Henrique da Mota; Alexander Dimic; Nihal A Fathi; Gianfranco Ferraccioli; Wataru Fukuda; Pál Géher; Feride Gogus; Najia Hajjaj-Hassouni; Hisham Hamoud; Glenn Haugeberg; Dan Henrohn; Kim Horslev-Petersen; Ruxandra Ionescu; Dmitry Karateew; Reet Kuuse; Ieda Maria Magalhaes Laurindo; Juris Lazovskis; Reijo Luukkainen; Ayman Mofti; Eithne Murphy; Ayako Nakajima; Omondi Oyoo; Sapan C Pandya; Christof Pohl; Denisa Predeteanu; Mjellma Rexhepi; Sylejman Rexhepi; Banwari Sharma; Eisuke Shono; Jean Sibilia; Stanislaw Sierakowski; Fotini N Skopouli; Sigita Stropuviene; Sergio Toloza; Ivo Valter; Anthony Woolf; Hisashi Yamanaka Journal: Arthritis Res Ther Date: 2010-03-12 Impact factor: 5.156
Authors: Suzanne M M Verstappen; Kath D Watson; Mark Lunt; Katie McGrother; Deborah P M Symmons; Kimme L Hyrich Journal: Rheumatology (Oxford) Date: 2010-05-05 Impact factor: 7.580